Replies to post #133218 on Biotech Values

[oc631]

Their valuations are still too high

What's crazy is neither stock has support if this is a safety issue within the purine nuke class. Basically they are single asset companies considering their meager pipelines. What's going on in the heads of large pharma companies that were shopping for a nuke backbone for oral therapy?

If BMY/JNJ's latest NS5A/Protease combo succumbs to viral breakthrough, and the HCV purines prove unsafe, the scarcity value of a safe pyrimidine nucleotide could make PSI-7977 an even more valuable asset then we discussed.

I was never on board with the notion that a dual-nuke combination must be the answer for HCV

I wasn't either. One should do just fine. PSI-938 was developed to back-up the resistance profile of PSI-7977 against a resistant variant (282T) that was only drawn out under intensive lab testing.